by Raynovich Rod | Feb 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Life Science Stocks Surge Ahead From February Lows NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions...
by Raynovich Rod | Feb 3, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
But Momentum Is Easing As Investors Cash Out-IBB Is 5.5% Off Jan 22 Highs Caution Rules With Selling Pressure-Raise Cash to 15% January 2014 was up 12% which may be the best month ever in biotechnology at peak prices on January 22. But with the sector up over 62%...
by Raynovich Rod | Jan 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 12:40p NASDAQ Up 2% Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2. Thermo Fisher (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to...
by Raynovich Rod | Jan 28, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Plenty Of FirePower Left In Biotech-IBB Up 2.2% At $244 Biotechnology stocks have been quite volatile and not immune to downdrafts but today they made an impressive recovery. Nonetheless I would be selective and not trade the small cap high fliers unless you did your...
by Raynovich Rod | Jan 20, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
by Raynovich Rod | Jan 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Dec 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Santa Claus Making Fast Tracks Nasdaq is up 1% as of midday trading and life science stocks are strong across the board. The IBB is up 2.29%, XBI up 1.8 %.The holiday spirit pervades. Movers among the Rayno Life Science focus stocks are the usual suspects plus many...
by Raynovich Rod | Dec 9, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Weak Tape Today 12/10–Gilead (GILD) Down 4.4% on 15.5M Shares IBB ($218.81) down 1.33% on good volume. GILD fall could be reaction to Abbvie (ABBV $53.55) up 4.5% on Phase 3 Hepatitis C data. Virologic response of ABT-450r is 96% in Genotype 1 patients. Other...
